HUTCHMED (00013) rose over 5%, closing up 5.47% at HK$24.68 with trading volume of HK$112 million as of press time.

On the news front, HUTCHMED announced on September 5 that it will present the latest and updated data from multiple studies of its proprietary compounds at the 2025 World Conference on Lung Cancer (WCLC) to be held in Barcelona, Spain from September 6-9, 2025, and at the Chinese Society of Clinical Oncology (CSCO) 2025 Annual Meeting to be held in Jinan, China from September 10-14, 2025.

According to the announcement, the latest analysis results from the SACHI study, SAVANNAH study, and a Phase IIIb confirmatory study of savolitinib for the treatment of non-small cell lung cancer will be presented at the 2025 World Conference on Lung Cancer. Savolitinib is a potent, highly selective oral MET tyrosine kinase inhibitor (TKI) co-developed by AstraZeneca and HUTCHMED, and commercialized by AstraZeneca.

Data from the first-in-human Phase I clinical trial of HMPL-653 (a novel, selective, potent CSF-1R inhibitor) in Chinese patients with tenosynovial giant cell tumor will be presented for the first time at the 2025 CSCO Annual Meeting.